How do you pay?

How to pay the least

Ask for the cash price

Ojjaara

We didn’t find one.

  1. Ask your pharmacy for Ojjaara’s cash price, and one or two other pharmacies too.
  2. Ojjaara’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify GSK Patient Assistance Program (prescription medicines). Or call 1-866-728-4368.

See if you qualify 

Compare every option

Question
Brand nameOjjaara
Authorized genericmomelotinib
Regular genericmomelotinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Ojjaara?
The original
–
–

Brand nameThe maker’s card

OJJAARA Copay Program

Savings card from GSK

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

Sign up on ojjaaraco-pay.gsk.com 

Or call 1-844-447-5662.

In the maker’s words

“Eligible, commercially insured patients may pay as little as $0 for OJJAARA…”

From the maker’s offer on ojjaaraco-pay.gsk.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Ojjaara itself, from the same company, sold without the brand name, and usually for less. For now Ojjaara is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.

Source: the FDA label for Ojjaara (GlaxoSmithKline LLC), July 20, 2026. Full label on DailyMed 

Good to know